Norway: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Norway

The Norwegian prophylactic medicaments containing insulin market shrank slightly to $X in 2022, approximately mirroring the previous year. The market value increased at an average annual rate of +4.8% over the period from 2012 to 2022; however, the trend pattern indicated some noticeable fluctuations being recorded throughout the analyzed period. Over the period under review, the market hit record highs at $X in 2017; however, from 2018 to 2022, consumption failed to regain momentum.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Norway

In value terms, prophylactic medicaments containing insulin production shrank modestly to $X in 2022 estimated in export price. Overall, the total production indicated a moderate increase from 2012 to 2022: its value increased at an average annual rate of +4.3% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, production increased by +2.2% against 2020 indices. The pace of growth was the most pronounced in 2013 with an increase of 67%. Over the period under review, production reached the peak level at $X in 2017; however, from 2018 to 2022, production remained at a lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports from Norway

In 2022, overseas shipments of medicaments containing insulin but not antibiotics in measured doses increased by 4,441% to X tons, rising for the second year in a row after six years of decline. In general, exports, however, showed a drastic downturn. Over the period under review, the exports attained the maximum at X tons in 2014; however, from 2015 to 2022, the exports failed to regain momentum.

In value terms, prophylactic medicaments containing insulin exports soared to $X in 2022. Overall, exports, however, continue to indicate a dramatic downturn. Over the period under review, the exports reached the peak figure at $X in 2014; however, from 2015 to 2022, the exports remained at a lower figure.

Exports by Country

Poland (X kg) was the main destination for prophylactic medicaments containing insulin exports from Norway, with a 69% share of total exports. Moreover, prophylactic medicaments containing insulin exports to Poland exceeded the volume sent to the second major destination, Slovakia (X kg), twofold.

From 2012 to 2022, the average annual growth rate of volume to Poland was relatively modest. Exports to the other major destinations recorded the following average annual rates of exports growth: Slovakia (+23.7% per year) and Germany (-49.1% per year).

In value terms, Poland ($X) emerged as the key foreign market for medicaments containing insulin but not antibiotics in measured doses exports from Norway, comprising 75% of total exports. The second position in the ranking was held by Slovakia ($X), with a 24% share of total exports.

From 2012 to 2022, the average annual rate of growth in terms of value to Poland was relatively modest. Exports to the other major destinations recorded the following average annual rates of exports growth: Slovakia (-9.5% per year) and Germany (-54.3% per year).

Export Prices by Country

In 2022, the average prophylactic medicaments containing insulin export price amounted to $X per kg, which is down by -43.3% against the previous year. Over the period under review, the export price saw a abrupt decline. The most prominent rate of growth was recorded in 2019 when the average export price increased by 544% against the previous year. The export price peaked at $X per kg in 2013; however, from 2014 to 2022, the export prices remained at a lower figure.

Prices varied noticeably by country of destination: amid the top suppliers, the country with the highest price was Germany ($X per kg), while the average price for exports to Slovakia ($X per kg) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to Denmark (+28.4%), while the prices for the other major destinations experienced mixed trend patterns.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports into Norway

In 2022, imports of medicaments containing insulin but not antibiotics in measured doses into Norway declined sharply to X tons, which is down by -20.7% compared with 2021. Over the period under review, imports showed a deep contraction. The most prominent rate of growth was recorded in 2019 with an increase of 39% against the previous year. Imports peaked at X tons in 2015; however, from 2016 to 2022, imports remained at a lower figure.

In value terms, prophylactic medicaments containing insulin imports shrank to $X in 2022. Overall, imports recorded a abrupt decrease. The growth pace was the most rapid in 2021 when imports increased by 57%. Over the period under review, imports reached the maximum at $X in 2012; however, from 2013 to 2022, imports failed to regain momentum.

Imports by Country

Denmark (X tons), Germany (X tons) and the Czech Republic (X tons) were the main suppliers of prophylactic medicaments containing insulin imports to Norway, with a combined 96% share of total imports.

From 2012 to 2022, the most notable rate of growth in terms of purchases, amongst the main suppliers, was attained by the Czech Republic (with a CAGR of +18.2%), while imports for the other leaders experienced a decline.

In value terms, the largest prophylactic medicaments containing insulin suppliers to Norway were Denmark ($X), Germany ($X) and the Czech Republic ($X), together comprising 96% of total imports.

In terms of the main suppliers, the Czech Republic, with a CAGR of +29.4%, saw the highest growth rate of the value of imports, over the period under review, while purchases for the other leaders experienced mixed trend patterns.

Import Prices by Country

In 2022, the average prophylactic medicaments containing insulin import price amounted to $X per ton, picking up by 16% against the previous year. Overall, import price indicated modest growth from 2012 to 2022: its price increased at an average annual rate of +1.2% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, prophylactic medicaments containing insulin import price increased by +58.3% against 2020 indices. The growth pace was the most rapid in 2018 an increase of 47%. As a result, import price attained the peak level of $X per ton. From 2019 to 2022, the average import prices failed to regain momentum.

Average prices varied somewhat amongst the major supplying countries. In 2022, amid the top importers, the country with the highest price was the Czech Republic ($X per ton), while the price for Germany ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Germany (+10.7%), while the prices for the other major suppliers experienced mixed trend patterns.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :